318 related articles for article (PubMed ID: 17719654)
1. The therapeutic effect of glatiramer acetate in a murine model of inflammatory bowel disease is mediated by anti-inflammatory T-cells.
Aharoni R; Sonego H; Brenner O; Eilam R; Arnon R
Immunol Lett; 2007 Oct; 112(2):110-9. PubMed ID: 17719654
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory therapeutic effect of glatiramer acetate on several murine models of inflammatory bowel disease.
Aharoni R; Kayhan B; Brenner O; Domev H; Labunskay G; Arnon R
J Pharmacol Exp Ther; 2006 Jul; 318(1):68-78. PubMed ID: 16624971
[TBL] [Abstract][Full Text] [Related]
3. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ.
Aharoni R; Kayhan B; Eilam R; Sela M; Arnon R
Proc Natl Acad Sci U S A; 2003 Nov; 100(24):14157-62. PubMed ID: 14614135
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease -- Dextran induced colitis.
Aharoni R; Brenner O; Cohen A; Arnon R
Int Immunopharmacol; 2008 Nov; 8(11):1578-88. PubMed ID: 18664394
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of glatiramer acetate treatment on syndecan-1 expression in dextran sodium sulfate colitis.
Yablecovitch D; Shabat-Simon M; Aharoni R; Eilam R; Brenner O; Arnon R
J Pharmacol Exp Ther; 2011 May; 337(2):391-9. PubMed ID: 21310817
[TBL] [Abstract][Full Text] [Related]
6. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease.
Sun Y; Wu XX; Yin Y; Gong FY; Shen Y; Cai TT; Zhou XB; Wu XF; Xu Q
Biochem Pharmacol; 2010 Jan; 79(2):229-38. PubMed ID: 19698701
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.
Gonzalez-Rey E; Delgado M
Gastroenterology; 2006 Dec; 131(6):1799-811. PubMed ID: 17087944
[TBL] [Abstract][Full Text] [Related]
9. Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice.
Elinav E; Waks T; Eshhar Z
Gastroenterology; 2008 Jun; 134(7):2014-24. PubMed ID: 18424268
[TBL] [Abstract][Full Text] [Related]
10. Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Yao Y; Han W; Liang J; Ji J; Wang J; Cantor H; Lu L
Eur J Immunol; 2013 Jan; 43(1):125-36. PubMed ID: 23002042
[TBL] [Abstract][Full Text] [Related]
11. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile.
Daniel C; Sartory NA; Zahn N; Radeke HH; Stein JM
J Pharmacol Exp Ther; 2008 Jan; 324(1):23-33. PubMed ID: 17911375
[TBL] [Abstract][Full Text] [Related]
12. Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis.
Mencarelli A; Distrutti E; Renga B; Cipriani S; Palladino G; Booth C; Tudor G; Guse JH; Hahn U; Burnet M; Fiorucci S
Eur J Pharmacol; 2011 Aug; 665(1-3):29-39. PubMed ID: 21554873
[TBL] [Abstract][Full Text] [Related]
13. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
14. R-spondin1, a novel intestinotrophic mitogen, ameliorates experimental colitis in mice.
Zhao J; de Vera J; Narushima S; Beck EX; Palencia S; Shinkawa P; Kim KA; Liu Y; Levy MD; Berg DJ; Abo A; Funk WD
Gastroenterology; 2007 Apr; 132(4):1331-43. PubMed ID: 17408649
[TBL] [Abstract][Full Text] [Related]
15. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease.
Mencarelli A; Renga B; Palladino G; Distrutti E; Fiorucci S
Biochem Pharmacol; 2009 Nov; 78(9):1214-23. PubMed ID: 19555671
[TBL] [Abstract][Full Text] [Related]
16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.
Lee J; Lee EN; Kim EY; Park HJ; Chang CY; Jung DY; Choi SY; Lee SK; Lee KW; Kwon GY; Joh JW; Kim SJ
Immunol Lett; 2005 Nov; 101(2):210-6. PubMed ID: 16026855
[TBL] [Abstract][Full Text] [Related]
17. The opioid antagonist naltrexone improves murine inflammatory bowel disease.
Matters GL; Harms JF; McGovern C; Fitzpatrick L; Parikh A; Nilo N; Smith JP
J Immunotoxicol; 2008 Apr; 5(2):179-87. PubMed ID: 18569389
[TBL] [Abstract][Full Text] [Related]
18. A role for proteinase-activated receptor-1 in inflammatory bowel diseases.
Vergnolle N; Cellars L; Mencarelli A; Rizzo G; Swaminathan S; Beck P; Steinhoff M; Andrade-Gordon P; Bunnett NW; Hollenberg MD; Wallace JL; Cirino G; Fiorucci S
J Clin Invest; 2004 Nov; 114(10):1444-56. PubMed ID: 15545995
[TBL] [Abstract][Full Text] [Related]
19. Aggravation of intestinal inflammation by depletion/deficiency of gammadelta T cells in different types of IBD animal models.
Kühl AA; Pawlowski NN; Grollich K; Loddenkemper C; Zeitz M; Hoffmann JC
J Leukoc Biol; 2007 Jan; 81(1):168-75. PubMed ID: 17041003
[TBL] [Abstract][Full Text] [Related]
20. Blockade of CXCL12/CXCR4 axis ameliorates murine experimental colitis.
Mikami S; Nakase H; Yamamoto S; Takeda Y; Yoshino T; Kasahara K; Ueno S; Uza N; Oishi S; Fujii N; Nagasawa T; Chiba T
J Pharmacol Exp Ther; 2008 Nov; 327(2):383-92. PubMed ID: 18716065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
